Company profile: Barentz
1.1 - Company Overview
Company description
- Provider of specialty ingredients for pharmaceutical, personal and home care, food & nutrition, and animal nutrition markets worldwide, representing world-class suppliers and Barentz-owned producers. Includes APIs, excipients, nutraceuticals, functional actives, intermediates, alternative proteins, clean label, sugar/sodium reduction, fortification, and animal nutrition concepts, plus technical/formulation support and supply chain, warehousing and transport solutions.
Products and services
- Animal Nutrition Ingredients: Supplies performance-focused ingredients and concepts engineered to improve feed efficiency and productivity while contributing to animal health and wellbeing
- Food & Beverage Ingredients: Offers clean-label components including alternative protein sources, sugar and sodium reduction assemblies, and fortification products with vitamins and minerals
- Pharmaceutical Ingredients: Delivers specialty-grade excipients, nutraceutical and functional food actives, active pharmaceutical ingredients (APIs), and pharmaceutical intermediates for use in pharmaceutical manufacturing
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Barentz
The Medicines Company
HQ: United States
Website
- Description: Provider of innovative, cost-effective medicines to the worldwide hospital marketplace, focused on advancing treatment of critical care patients. Markets Angiomax(R) (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, and Cleviprex(R).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full The Medicines Company company profile →
ViroPharma
HQ: United States
Website
- Description: Provider of biopharmaceutical products addressing serious diseases, focused on therapies used by physician specialists or in hospital settings; develops and commercializes treatments, with two marketed products and three development programs, including Vancocin HCl capsules.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ViroPharma company profile →
Lewis and Clark Pharmaceuticals
HQ: United States
Website
- Description: Provider of early-stage pharmaceutical development targeting treatments for arthritis, diabetes, glaucoma, and atherosclerosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lewis and Clark Pharmaceuticals company profile →
Paloma Pharmaceuticals
HQ: United States
Website
- Description: Provider of early-stage drug development focusing on pathologies showing an aberrant up-regulation of the PI3K/Akt/mTOR pathway, including cancer, ocular diseases (macular degeneration and diabetic retinopathy), arthritis, fibrotic diseases (renal and pulmonary fibrosis), and CNS (epilepsy and neurodegenerative).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Paloma Pharmaceuticals company profile →
Endacea
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies targeting the A1 adenosine receptor, including L-97-1, an intravenous A1 adenosine receptor antagonist for sepsis and acute renal failure, and a mutant plasmid cDNA for cancer administered as an intratumor injection. Both programs are in the preclinical stage.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Endacea company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Barentz
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Barentz
2.2 - Growth funds investing in similar companies to Barentz
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Barentz
4.2 - Public trading comparable groups for Barentz
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →